MedPath

Evaluation of the effectiveness of metformin prophylaxis in preventing risperidone-induced hyperprolactinemia in children and adolescents

Phase 3
Recruiting
Conditions
Hyperprolactinemia caused by risperidone.
Hyperprolactinemia
E22.1
Registration Number
IRCT20200304046698N2
Lead Sponsor
Shahid Beheshti University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
40
Inclusion Criteria

Patient and parent consent to participate in the study
Age 10 to 18 years
Psychiatric necessity for taking risperidone
Normal prolactin at the beginning of the study

Exclusion Criteria

Allergy to risperidone or metformin
Need to change risperidone or add a second drug due to lack of control of psychiatric symptoms
Intolerable or severe side effects with risperidone and metformin
Occurrence of short-term physical symptoms of hyperprolactinemia
Previous or current history of neurological disease (current seizure disorders, history of head trauma, migraine)
Previous or current history of systemic disease (blood, endocrine, liver, thyroid, kidney, metabolic disease)
Smoking and any type of drug
Taking medication that interacts with metformin
Positive pregnancy test in teenage girls
Taking any type of drug affecting the plasma level of prolactin (including other antipsychotics, antidepressants, and stimulants)

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath